ArticleCancer medicine2025
Prediction of HER2-Low Breast Cancer via Multimodal Ultrasound Imaging.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prediction of HER2-Low Breast Cancer via Multimodal Ultrasound Imaging.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeHuman epidermal growth factor receptor 2 (HER2) is a key biomarker for clinical management and prognostic evaluation of breast cancer patients. This study was aimed at assisting the preoperative and non-invasive prediction of HER2-low breast cancer using multimodal ultrasound imaging and clinicopathological indicators, providing valuable imaging information for clinical precision diagnosis and personalized treatment strategies, especially in the application of antibody-drug conjugates such as T-DXd. MATERIALS AND
methodsThis retrospective study included 147 pathologically confirmed breast cancer patients from two institutions: 101 in the training set and 46 in the external validation set. All patients underwent multimodal ultrasound (grayscale, color Doppler, elastography, and contrast-enhanced imaging) and had complete clinicopathological data. Patients were categorized as HER2-negative, HER2-low, or HER2-positive based on immunohistochemistry. Logistic regression was used to construct predictive models.
resultsCompared with the HER2-negative group, low Ki-67, PR positivity, longer rise time (RT), and lower Emax values were independent predictors of HER2-low status (p < 0.05), yielding an AUC of 0.876, sensitivity 0.833, and specificity 0.781. Compared with HER2-positive cancers, HER2-low cases showed low Ki-67, ER/PR positivity, low Emax, and a DVPC pattern characterized by an initial increase followed by a subsequent decline as independent predictors (p < 0.05), with an AUC of 0.929, sensitivity 0.905, and specificity 0.856. External validation confirmed robust model performance (AUC = 0.925 and 0.918 for HER2-low vs. negative and positive, respectively).
conclusionA model integrating multimodal ultrasound and clinicopathological factors effectively predicts HER2-low breast cancer, offering valuable imaging-based support for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.